Teva/Actavis Generics

Company snapshot

Actavis UT, Inc. develops, manufactures, and sells generic pharmaceutical products. Actavis UT, Inc. was formerly known as Watson Laboratories, Inc. and changed its name to Actavis Laboratories UT, Inc. in January 2015. The company was incorporated in 1992 and is based in Salt Lake City, Utah. Actavis UT, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Teva/Actavis Generics. Not investment advice.

• What is Teva/Actavis Generics?

  Teva Generics is a pharma organization headquartered in EU. Primary therapeutic focus areas include Multiple Myeloma, Neoplasms, Eosinophilic Asthma, Asthma. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA,

• Is Teva/Actavis Generics publicly traded?

  Teva/Actavis Generics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Teva/Actavis Generics develop or market?

  We link 1 drug profile(s) where Teva/Actavis Generics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/generics-uk-limited#company-drugs.

• What are the latest developments for Teva/Actavis Generics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Teva/Actavis Generics focus on?

  Teva/Actavis Generics focuses on Multiple Myeloma, Neoplasms, Eosinophilic Asthma based on our analysis of their pipeline programs and drug development activities.